Compare Ascendis Pharma A/S (ASND) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs AT&T Inc. — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while AT&T Inc. trades at $21.28 (market cap $146.82B). The key difference: AT&T Inc. is far larger — about 8.3× Ascendis Pharma A/S's market cap, and AT&T Inc. pays a 5.25% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | T | |
|---|---|---|
Market Cap | $17.74B | $146.82B |
Sector | Health | Media |
52-Week High | $277.18 | $29.62 |
52-Week Low | $163.32 | $20.49 |
Enterprise Value | $18.11B | $292.17B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
AT&T (T) trades at $21.13, up 0.48% today but near 52-week lows, with a bearish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 7.11, net income margin of 16.94%, and three consecutive quarterly EPS beats. Recent news highlights SpaceX competition concerns, though the company maintains robust cash flow and a 5.3% dividend yield.
The outlook is mixed: valuation appears attractive with analyst consensus target of $26.43 (25% upside), but technical weakness and competitive threats pose risks. Investment opportunity lies in income generation and potential rebound if execution continues, while key risks include debt levels and industry disruption from new entrants.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
